Biogen Idec Reports Full Year and Fourth Quarter 2006 Results
Business Wire (press release) - San Francisco,CA,USA
Second, we successfully launched two products: RITUXAN in rheumatoid arthritis and TYSABRI for multiple sclerosis in the US and Europe. ...

Biogen Idec 4Q Profit Doubles
Washington Post - Washington,DC,USA
Although Tysabri recorded just $30 million in sales in the latest quarter, Biogen Idec's future growth is tied heavily to the next-generation MS drug. ...
See all stories on this topic

Thu: Why Teva makes me mad
Globes - Rishon Le-Zion,Israel
(NYSE: ELN) and its Tysabri, and it ended with the announcement of the departure of president and CEO Israel Makov, the man who took Teva from $3 billion ...

Bitter pill on the way
Unison.ie (subscription) - Bray,Ireland
In 2001, Elan and its research partner Biogen Idec withdrew their multiple sclerosis drug Tysabri after a link with progressive multifocal ...